Coeptis Therapeutics Holdings, Inc. (COEP)

0,3561 -0,0241 (-6,34%) Börsenschluss: 04:00PM EDT

Coeptis Therapeutics Holdings, Inc.

105 Bradford Road
Suite 420
Wexford, PA 15090
United States
(724) 934-6467
https://coeptistx.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 5

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. David Mehalick	Co-Founder, Chairman of the Board, CEO & President	360k	N/A	1969
Ms. Christine Elise Sheehy	Co-Founder and VP of Compliance & Corporate Secretary	151k	N/A	1968
Mr. Daniel Alexander Yerace	Co-Founder, VP of Operations & Director	360k	N/A	1983
Mr. Brian Cogley M.B.A.	Chief Financial Officer	208k	N/A	1987
Dr. Colleen Delaney M.D., M.Sc.	CSO & Chief Medical Officer	360k	N/A	1968

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.

Corporate Governance

Coeptis Therapeutics Holdings, Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.